Novigenix Sa

Novigenix is a precision medicine Tech Bio offering state-of-the-art ImmunoTranscriptomic liquid biopsy solutions with unprecedented predictive capabilities for precision development of novel therapeutics. Our AI-enabled ISO-13485 certified RNA analytic platform delivers ImmunoPD biomarkers, insights into mechanism of action and resistance, and early markers for severe toxicity to accelerate clinical development. These scalable solutions are currently adopted in a number of FDA clinical trials providing actionable insights across therapeutic modalities including ADCs, radioligand therapy, cellular therapies, therapeutic vaccines, and immunotherapies. The LITOSeek™ Liquid ImmunoTranscriptOmic platform has been optimized for mapping the response of patient immune system to onset of disease and therapeutic intervention. Proprietary analytical pipelines integrate patient multi-omics data with advanced Machine Learning and artificial intelligence approaches for early detection of disease, development of novel therapeutics, and drug target discovery.